ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "methotrexate (MTX)"

  • Abstract Number: 022 • 2020 Pediatric Rheumatology Symposium

    Association of Plasma Metabolomic Profiles with Methotrexate Response in Juvenile Idiopathic Arthritis

    Ryan Funk1 and Mara Becker 2, 1University of Kansas, Leawood, Kansas, 2Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill

    Background/Purpose: Despite efforts to identify biomarkers to guide therapy in the treatment of juvenile idiopathic arthritis (JIA), drug therapy remains a trial-and-error process. In the…
  • Abstract Number: 1236 • 2019 ACR/ARP Annual Meeting

    Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase in Uncontrolled Gout Patients in a Community Rheumatology Practice

    John A. Albert1, Tony Hosey 2 and Brian LaMoreaux 2, 1Rheumatic Disease Center, Milwaukee, IL, 2Horizon Therapeutics plc, Lake Forest, IL

    Background/Purpose: Pegloticase is an infused biologic for uncontrolled gout patients that is highly effective but can cause anti-drug antibodies that lead to a lack of…
  • Abstract Number: 2386 • 2019 ACR/ARP Annual Meeting

    Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis

    Jesus Tornero1, Mercedes Alperi-López 2, Ivan Castellvi 3, Juan José de Agustín de Oro 4, Alejandro Escudero 5, Rosario Garcia-Vicuña 6, Miguel Angel González-Gay 7, Cristina Hidalgo 8, Esteban Rubio 9, Raimon Sanmarti 10, Núria Casamira 11 and Jaime Calvo-Alen 12, 1Hospital de Guadalajara, Guadalajara, Spain, 2Hospital Universitario Central de Asturias, Oviedo, Spain, 3Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 4Hospital Universitari Vall d’Hebron, Barcelona, Spain, 5IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 6Hospital Universitario de La Princesa, Madrid, Spain, 7Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 8Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, 9Rheumatology Department, University Hospital Virgen del Rocío, Sevilla, Spain, 10Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, 11Medical Department, Gebro Pharma S.A., Barcelona, Spain, 12Hospital Universitario Araba, Vitoria-Gasteiz, Spain

    Background/Purpose: Our aim was to develop recommendations for the management of methotrexate (MTX) when considering the combination with biological (b) or targeted synthetic (ts) disease…
  • Abstract Number: 1279 • 2019 ACR/ARP Annual Meeting

    Response Rate and Sustained Remission in Idiopathic Inflammatory Myopathies Receiving Conventional Immunosuppressive Stepwise Management

    Alain Sánchez-Rodríguez1, Citlallyc Josefina Gómez-Ruiz 2, Abril Montes-Yanes 2 and Gabriel Medrano-Ramírez 2, 1Hospital General de Mexico, Mexico City, Distrito Federal, Mexico, 2Hospital General de Mexico, Rheumatology Department, Ciudad de Mexico, Distrito Federal, Mexico

    Background/Purpose: Information regarding response rate and sustained remission in patients with idiopathic inflammatory myopathies (IIM), polymyositis (PM), dermatomyositis (DM), in Hispanics with non-biological treatment is…
  • Abstract Number: 2394 • 2019 ACR/ARP Annual Meeting

    Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit

    Lynn Price1, Phil Pouliot 1 and Lauren Schmitt 1, 1Spherix Global Insights, Exton, PA

    Background/Purpose: US rheumatologists have long agreed that methotrexate (MTX) is the backbone of rheumatoid arthritis (RA) treatment, and while comfort with biologic/JAK monotherapy is growing,…
  • Abstract Number: 1338 • 2019 ACR/ARP Annual Meeting

    Joint-specific Responses to Tofacitinib and Methotrexate in Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Start

    Mojca Frank-Bertoncelj1, Oliver Distler 2, Tim Killeen 3, Kenneth Kwok 4, Lisy Wang 5, Caroline Ospelt 1 and Adrian Ciurea 1, 1University Hospital Zürich, Zürich, Switzerland, 2Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, 3Pfizer AG, Zürich, Switzerland, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Groton, CT

    Background/Purpose: Despite systemic inflammatory cues, RA affects synovial joints variably. Tofacitinib is an oral JAK inhibitor for the treatment of RA. Previous post hoc analyses…
  • Abstract Number: 2401 • 2019 ACR/ARP Annual Meeting

    Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate

    Thierry Dervieux1, Joel Kremer 2, Kelley Brady 1, Chihiro Takahashi 3, Tsutomu Takeuchi 4 and Yuko Kaneko 5, 1Exagen, Vista, CA, 2Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY, 3Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, 4Keio University Hospital Division of Rheumatology, Tokyo, Japan, 5Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan

    Background/Purpose: Methotrexate (MTX) is an anti-folate prodrug activated to MTX polyglutamates (MTXPGs). Japanese Rheumatoid Arthritis (RA) patients are thought to have heightened sensitivity to MTX…
  • Abstract Number: 1436 • 2019 ACR/ARP Annual Meeting

    Analysis of Adverse Events of Methotrexate (MTX), bDMARDs and Tofacitinib (TOFA) Reported to Pharmaceuticals and Medical Devices Agency (PMDA), Japan

    Naonori Tsuda1, Shigeko Inokuma 2, Kenichi Hiraga 3, Yoshinori Masui 3 and Toshikazu Kano 3, 1Kohondai Hospital, National Center for Global health and Medicine, Ichikawa, Chiba, Japan, 2Chiba Central Medical Center, Ichikawa, Chiba, Japan, 3Kohnodai Hospital, National Center for Global health and Medicine, Ichikawa, Chiba, Japan

    Background/Purpose: Among DMARDs (disease modifying anti-rheumatic drugs), methotrexate (MTX), bDMARDs (biologic DMARDs) and JAK (Janus kinase) inhibitors are the major. Many adverse events of these…
  • Abstract Number: 2404 • 2019 ACR/ARP Annual Meeting

    Does Combined Therapy Affects Adherence in Rheumatoid Arthritis?

    Iván de Jesús Hernández-Galarza 1, Rita Pineda-Sic1, Marielva Castro-Gonzalez 1, Diana Elsa Flores-Alvarado 1, Octavio Ilizaliturri-Guerra 1, Rodolfo Uriarte-Botello 1 and Dionicio Galarza-Delgado 1, 1Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico

    Background/Purpose: Treatment adherence in Rheumatoid Arthritis (RA) patients vary from 30 to 80%. It is important to identify the associated factors to a low adherence,…
  • Abstract Number: 1441 • 2019 ACR/ARP Annual Meeting

    Is Background Methotrexate Still Advantageous in Extending TNF Drug Survival in the Elderly: An Analysis of the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis

    Katie Bechman1, Anuoluwapo Oke 2, Mark Yates 3, Sam Norton 3, Elaine Denderson 4, Andrew Cope 5 and James Galloway 2, 1Kings College London, London, England, United Kingdom, 2Kings College London, London, United Kingdom, 3Kings College London, London, 4MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, 5Academic Rheumatology, King's College London, London, United Kingdom

    Background/Purpose: Long-term observational data from national registries in rheumatoid arthritis allow the examination of TNF drug survival rates. Despite a good initial response to a…
  • Abstract Number: 2476 • 2019 ACR/ARP Annual Meeting

    Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA

    Alexis Ogdie1, Ervant Maksabedian 2, Bradley Stolshek 2, Yomei Shaw 3 and Kaleb Michaud 4, 1University of Pennsylvania, Philadelphia, PA, 2Amgen Inc., Thousand Oaks, CA, 3FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, 4FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS

    Background/Purpose: Methotrexate (MTX) is generally well tolerated in rheumatoid arthritis (RA) but little is known about the tolerability of MTX in psoriatic arthritis (PsA).  One…
  • Abstract Number: 1533 • 2019 ACR/ARP Annual Meeting

    The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis

    Laura Coates1, Joseph Merola 2, Philip Mease 3, Alexis Ogdie 4, Dafna Gladman 5, Vibeke Strand 6, Leonieke van Mens 7, Lyrica Liu 8, Priscilla K Yen 8, David Collier 8, Gregory Kricorian 8, James Chung 8 and Philip Helliwell 9, 1University of Oxford, Oxford, United Kingdom, 2Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, 3Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, 4Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 5Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, 6Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 7University of Amsterdam, Amsterdam, Netherlands, 8Amgen Inc., Thousand Oaks, CA, 9University of Leeds, Leeds, United Kingdom

    Background/Purpose: Composite measures of disease activity are used in psoriatic arthritis (PsA), but their relative performance and contributions of individual components to overall scores are…
  • Abstract Number: 2860 • 2019 ACR/ARP Annual Meeting

    Perturbation of the Human Gut Microbiome by Methotrexate Contributes to the Resolution of Inflammation and Autoimmune Disease

    Renuka Nayak1, Margaret Alexander 1, Kye Stapleton-Grey 2, Carles Ubeda 3, Jose Scher 4 and Peter Turnbaugh 1, 1UCSF, San Francisco, 2Carnegie Mellon, Pittsburg, 3Centro Superior de Investigación en Salud Pública - FISABIO, Valencia, Spain, 4Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY

    Background/Purpose: The trillions of microorganisms (microbiota) found within the human gut play a critical role in shaping the immune system, yet these complex microbial communities…
  • Abstract Number: 1759 • 2019 ACR/ARP Annual Meeting

    Methotrexate in Patients with Hand Erosive Osteoarthritis Refractory to Usual Treatments: A Randomized, Double-blind, Placebo-controlled Trial

    stéphanie Ferrero 1, Ruth Wittoek 2, Edem Allado 3, Coralie Cruzel 4, Véronique Breuil 1, Liana Euller Ziegler 5, Damien louille 6, Christian Roux7 and Joel Kremer 8, 1University of Nice, nice, France, 2Ghent University Hospital, Gent University, Gent, Belgium, 3Centre Hospitalier Universitaire de Nancy, Nancy, France, 4Université Cote d'Azur, nice, France, 5PUPH CHU NICE, nice, France, 6Université Cote d'Azur, Nancy, France, 7Université Cote d'Azur, Nice, 8Albany Medical College, Albany, NY

    Background/Purpose: No studies have assessed the effect of methotrexate (MTX) in osteoarthritis of the hand (HOA). The purpose of our study was to examine the…
  • Abstract Number: 1890 • 2019 ACR/ARP Annual Meeting

    Methotrexate Adverse Events in a Randomized Double-Blind Placebo-Controlled Trial:Results from the Cardiovascular Inflammation Reduction Trial (CIRT)

    Daniel Solomon1, Robert Glynn 2, Elizabeth Karlson 3, Fengxin Lu 3, Cassandra Corrigan 3, Joshua Colls 3, Chang Xu 3, Jean MacFadyen 3, Medha Barbhaiya 4, Nancy Berliner 3, Paul Dellaripa 3, Brendan Everett 3, Sara Hammond 3, Meredith Murray 3, Deepak Rao 3, Susan Ritter 5, Anna Rutherford 5, Jeffrey Sparks 3, Jacklyn Stratton 5, Dong Suh 3, Sara K. Tedeschi 6, Kathleen Vanni 3, Nina Paynter 5 and Paul Ridker 5, 1Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, 2Harvard Medical School - Boston, MA, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 5Brigham and Women's Hospital, Boston, 6Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA

    Background/Purpose: Prior observational studies have estimated the risk of adverse events with low dose methotrexate (MTX). However, prior randomized controlled trials (RCT) were too small…
  • 1
  • 2
  • 3
  • …
  • 16
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology